AURA - Aura Bio Analyst Consensus Forecast

Symbol and logo of brand Aura Biosciences Inc (AURA)

This price chart for Aura Biosciences, Inc. (AURA) reflects the dynamics of a company whose ophthalmological logistics rely on strict temperature control to ensure therapy safety. The current metric stands at 16.58. The business is optimizing costs by outsourcing initial tests to external academic centers. The strategy relies on an asset-light model: development is conducted in the US, while drug production is entrusted to major contract manufacturing organizations.

AURA: Aura Biosciences, Inc. Analyst Consensus Forecast 07/04/2022 - 11/17/2026

Analytical breakdowns for Aura Corp (AURA)

- stock value and consensus price forecast:
Fundamental company analysis:Aura Biosciences (AURA)
Original product of Aura Bio

Developing oncotherapy through VDC projects and M&A patent deals, Aura Biosciences, Inc. (AURA) relies on expert valuations of its innovations. The weighted average target price aggregates investment bank forecasts, measuring the gap between the fundamental potential of assets and their market value. A consistent divergence between share prices and the current consensus target signals correction risks should the pace of the business's clinical recovery slow.

Competing companies

ONC - Average Forecast Price|Analyst Consensus Forecast HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines Corp - Price Target Chart|AAPG - Price Target Chart|Average Forecast Price cgoncology.com|UroGen (URGN) - Price Target Chart|Broker Consensus Forecast BCAX|PSNL (Personalis Genomics) - Analyst Consensus Forecast|Consensus Target Erasca Corp (ERAS)|Analyst Consensus Forecast DCTH|Analyst Consensus Forecast ymabs.com (YMAB)|Price Target Chart candeltx.com CADL|ARAY: Broker Consensus Forecast|SELLAS Life Sciences Group Inc. - Analyst Consensus Forecast|Actuate Therapeutics, Inc (ACTU) - Consensus Target|CTOR: Analyst Consensus Forecast|Average Forecast Price TuHURA (HURA)|Price Target Chart Protara Therapeutics, Inc.|FATE: Fair Value Consensus|Consensus Target WHWK (Aadi Bioscience, Inc.)|TCRX (TScan Therapeutics, Inc.) - Fair Value Consensus|Analyst Consensus Forecast CSBR (Champions Oncology)|XBIT - Consensus Target|CVM - Price Target Chart|OSTX - Analyst Consensus Forecast|Radiopharm Theranostics Limited (RADX) - Price Target Chart|Artiva Biotherapeutics Inc. - Fair Value Consensus|ANL (Adlai Nortye Limited) - Analyst Consensus Forecast|Average Forecast Price Veru VERU|Consensus Target TPST (Tempest Therapeutics)|Analyst Median Target Xilio Therapeutics Inc|Analyst Consensus Forecast RENB (Renovaro)|Analyst Consensus Forecast Mural Oncology plc MURA|Kairos Pharma Limited - Analyst Consensus Forecast|OKUR - Analyst Consensus Forecast|w2.cytomed.sg (GDTC) - Price Target Chart|CRIS - Analyst Median Target|Price Target Chart Apollomics, Inc.|Tharimmune Corporation (THAR) - Analyst Median Target|Analyst Consensus Forecast ADVB|GNPX - Average Forecast Price|Calidi Biotherapeutics - Consensus Target|SBFM: Broker Consensus Forecast|XBIO: Consensus Target|Analyst Median Target Salarius Pharmaceuticals SLRX|PPBT: Analyst Consensus Forecast|AON - Fair Value Consensus|Consensus Target BGNE|CKPT (Checkpoint Therapeutics, Inc) - Analyst Forecast Prices|Price Target Chart Elevation Oncology Inc. (ELEV)|Consensus Target iCAD ICAD|Price Target Chart Ikena Oncology IKNA|Analyst Median Target Notable Labs (NTBL)|Viracta Therapeutics - Analyst Consensus Forecast|Average Forecast Price MorphoSys Inc|NAYA: Analyst Consensus Forecast|Ascentage (AAPGV) - Analyst Consensus Forecast